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Abstract
Background: Patients with supraventricular tachycardia (SVT) and patients with coronary artery 
disease (CAD) often present with similar symptoms (chest pain, shortness of breath), similar electrocar-
diographic changes and elevated high-sensitivity troponin (Tn). It is not clear whether troponin reflects 
critical CAD or is elevated due to other causes in patients presenting with SVT. The aim of this study 
was to assess the role of elevated troponin in patients presenting with SVT. 
Methods: Patients undergoing radiofrequency ablation (RFA) for SVT and simultaneous coronary an-
giography at the Heart Centre Lucerne, Switzerland between January 2010 and October 2014 were in-
cluded in this analysis. Significant CAD was defined as diameter-stenosis ≥ 75% in vessels > 2.0 mm.  
The level of Tn was compared between patients with the presence or absence of CAD on coronary angi-
ography. A Tn value of ≥ 0.014 µg/L was considered as elevated.
Results: During the study period a total of 473 patients underwent RFA for SVT. The study population 
consisted of 326 patients (69%, mean age 60 ± 12 years) who underwent invasive coronary angiogra-
phy during the same session. The prevalence of significant CAD was 14% (45/326 patients). The highest 
prevalence of CAD was found in patients with atrial flutter (35%, 18/45 patients). Tn was elevated in 
83% (10/12 patients) with significant CAD and in 47% (26/55 patients) without CAD. 
Conclusions: The prevalence of CAD is low in patients with SVT, which questions the role of routine 
invasive coronary angiography during RFA. Tn measurement did not reliably exclude or confirm CAD 
in these patients. (Cardiol J 2017; 24, 6: 642–648)
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supraventricular tachycardia, high-sensitivity troponin, radiofrequency ablation
Introduction
Supraventricular tachycardias (SVT) are 
amongst the most common cardiac arrhythmias 
and are related to significant morbidity and mor-
tality [1, 2]. SVT can be paroxysmal, sometimes 
persistent or rarely life threatening [1]. The 
prevalence of paroxysmal SVT is estimated to 
be 3.5% at an incidence of 35 per 100,000 person 
years [3]. Age influences the occurrence of SVT 
with atrial fibrillation (AF) mainly affecting the 
older population. The SVT population is younger 
than the population with other cardiovascular dis-
eases (CVD) [3]. Furthermore, women are twice 
as likely to develop a paroxysmal SVT compared 
to men [3].
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Symptoms of patients presenting with SVT are 
heterogenic including palpitations, exercise intol-
erance, dizziness, dyspnea, angina, pre-syncope 
or syncope [1] and can very often not be clearly 
differentiated from symptoms related to other CVD 
(e.g. cardiac ischemia) [4, 5].
Coronary artery disease (CAD) is common in 
the Western world and can present as stable angina 
or as acute coronary syndrome (ACS) [6]. Prolonged 
cardiac ischemia leads to myocardial injury and car-
diac biomarkers are being used as a tool to diagnose 
and quantify myocardial damage [6]. New cardiac 
troponin (Tn) assays have a high sensitivity to detect 
myocardial injury [7, 8] and are now widely used in 
clinical practice. Increased Tn is not only a marker 
for ischemic heart disease and it is well known that 
several more conditions can be associated with el-
evated Tn: e.g. heart failure, myocarditis, dissection 
of the aorta and chronic renal failure [9].
Patients with SVT are often assessed in the 
emergency department (ED) and cardiac biomark-
ers are regularly measured in order to exclude 
acute myocardial injury requiring percutaneous or 
surgical revascularization. In patients with SVT, 
elevated Tn-levels may be observed [5] but case 
reports and small case series indicate that elevated 
Tn in patients with SVT does not necessarily indi-
cate the presence of CAD [10–12]. 
The aim of this study was to highlight the role 
of elevated Tn in patients presenting with SVT and 
undergoing invasive coronary angiography. 
Methods
This was a retrospective study performed in 
the Heart Centre Lucerne, Luzerner Kantons-
spital, Lucerne, Switzerland. The Heart Centre 
Lucerne is a tertiary care center performing > 350 
radiofrequency-ablations (RFA) and 2500 coronary 
angiograms per year. 
Study populations
The cohort consisted of patients undergoing 
RFA for SVT who underwent invasive coronary 
angiography in the same session. The procedure 
took place within 7 days after the presentation of 
the patients in our ED. Coronary angiography was 
performed as part of routine clinical care to exclude 
relevant CAD. The study period lasted from Janu-
ary 2010 to October 2014. 
Supraventricular tachycardia
The following categories of SVT’s were treat-
ed: AF, atrial flutter (AFL), atrioventricular nodal 
re-entry tachycardia (AVNRT), atrioventricular re-
entry tachycardia (AVRT), atrial tachycardia (AT). 
Troponin analysis
In patients presenting with an acute episode 
of SVT in our ED plasma samples were analyzed 
for high-sensitivity troponin (Tn) using the Roche 
Cobras e601 device. An increased Tn-level was 
defined at a value of ≥ 0.014 µg/L. The peak value 
within 24 h post-presentation was used for statisti-
cal analysis. Patients with point-of-care troponin 
measurements or troponin measurements of other 
hospitals were excluded.
Coronary angiography findings
Significant coronary artery stenosis was de-
fined as a diameter-stenosis ≥ 75% in two orthogo-
nal views in a coronary artery ≥ 2.0 mm. SYNTAX 
score was calculated using the web calculator [13].
Ethical considerations
Approval was granted by the regional ethical 
committee (Northwestern-Switzerland). All pa-
tients provided written informed consent for elec-
tronic data acquisition and follow-up examinations.
Statistical analysis
Continuous data are presented as mean value 
± the standard deviation and categorical date are 
given as n (%). Comparisons were performed with 
Student’s t test for continuous variables in cases 
of normal distribution and the Fisher’s exact test 
for categorical variables. The relationship between 
Tn-level and the Syntax score was evaluated by 
linear regression analysis. A two-sided p value 
< 0.05 was considered statistically significant. 
A logistic regression analysis was performed to 
identify predictors of CAD. The statistics were 
conducted with SPSS statistical program. The di-
agnostic value to detect significant coronary artery 
stenosis concerning sensitivity and specificity was 
admitted with a receiver operating characteristic 
(ROC) curve.
Results
During the study period a total of 473 patients 
underwent RFA. 326 (69%) patients underwent 
invasive coronary angiography to exclude CAD in 
the same session (Fig. 1) and these patients were 
included in the study population. 
Baseline characteristics of the study popula-
tion are shown in Table 1. Briefly, mean age was 
60 ± 12 years and 211 (65%) patients were male. 
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The most cardiovascular risk factor (cvRF) was 
arterial hypertension (43%, 141/326 patients) and 
73 (22%) patients of the study population had no 
cvRF. Palpitation was very common (87%, 283/326 
patients), 104 (32%) of the patients had atypical 
angina and 38 (12%) had typical angina. AF (33%, 
108/326 patients) and AVNRT (29%, 95/326 pa-
tients) were the most common arrhythmias. 
Prevalence of CAD
Of the 326 patients who underwent invasive 
coronary angiography, 45 (14%) patients had rel-
evant CAD and 281 (86%) patients had normal 
coronaries or minor CAD (Fig. 2). 
The comparison of cvRF depending on the 
presence or absence of significant CAD is shown 
in Table 2. In the univariate analysis arterial hy-
pertension, hypercholesterolemia and male gender 
were all significantly more common in patients with 
CAD (p < 0.001 for all). 
Table 3 compares the various presenting 
symptoms according to the presence or absence of 
significant CAD. No statistically significant differ-
ences in the prevalence of symptoms were found 
between the groups. 
The prevalence of CAD according to arrhyth-
mia type is shown in Table 4. CAD was numerically 
more common in patients presenting with AFL 
(35%, 18/51 patients). 
Role of Tn
A total of 67 patients (14% of the total popu-
lation) presented in the ED due to tachycardia 
and had Tn-levels measured in the acute episode. 
Table 1. Baseline characteristics of the study 
population (n = 326).
Demographics
Age [years] 60 ± 12
Sex, women 115 (35%)
Cardiovascular risk factors
No risk factors 73 (22%)
Arterial hypertension 141 (43%)
Hypercholesterolemia 120 (37%)
Diabetes mellitus 25 (8%)
Insulin dependent 10 (3%)
Smoking 85 (26%)
Positive family history 70 (21%)
Initial symptoms
Asymptomatic 5 (2%)
Typical angina 38 (12%)
Atypical angina 104 (32%)
Dyspnea 103 (32%)
Palpitation 283 (87%)
Syncope 20 (6%)
Type of SVT
AF 108 (33%)
AFL 51 (16%)
AF + AFL 29 (9%)
AVNRT 95 (29%)
AVRT 15 (5%)
WPW 15 (5%)
Ectopic AT 10 (3%)
AF — atrial fibrillation; AFL — atrial flutter; AVNRT — atrioventricular 
nodal re-entry tachycardia; AVRT — atrioventricular re-entry  
tachycardia; AT — atrial tachycardia; SVT — supraventricular  
tachycardia; WPW — Wolff-Parkinson-White syndrome
Figure 1. Definition of the study population; SVT — supraventricular tachycardia.
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Cardiac troponin was elevated (≥ 0.014 µg/L) in 
36 (54%) patients, who all underwent invasive 
coronary angiography. Increased Tn was found in 
83% (10/12 patients) with CAD and in 47% (26/55 
patients) without CAD (Table 5). Even patients 
with a Tn level > 1.0 µg/L had normal coronaries 
or minor CAD and on the other hand patients with 
CAD and SVT had normal Tn levels. Increased Tn 
did not correlate with significant coronary artery 
stenosis and a normal cTn-level did not exclude 
CAD (Figs. 2, 3).
Discussion
The main findings in the present study are: 
a) The prevalence of CAD is low in patients present- 
ing with SVT and undergoing RFA. b) Tn did not 
have a relevant impact on confirmation or exclusion 
of significant CAD in these patients. 
Symptoms of CAD and SVT may be very 
similar, electrocardiogram (ECG) is often diffi-
cult to interpret regarding ischemic signs and it 
is common practice in many centers to perform 
Table 2. Comparison of cardiovascular risk factors between patients with and without coronary artery 
disease (CAD) (n = 326).
CAD (n = 45; 14%) No CAD (n = 281; 86%) P
Age [years] 64 ± 8 59 ± 12 0.20
Male 40 (89%) 171 (61%) < 0.001
No risk factors 0 (0%) 73 (26%) 0.002
Arterial hypertension 34 (76%) 107 (38%) < 0.001
Hypercholesterolemia 33 (73%) 87 (31%) < 0.001
Diabetes mellitus 8 (18%) 17 (6%) 0.74
Insulin dependent 5 (11%) 5 (2%) 0.08
Nicotine 13 (29%) 72 (26%) 0.40
Positive family history 15 (33%) 55 (20%) 0.23
Table 3. Comparison of clinical characteristics between patients with and without coronary artery  
disease (CAD) (n = 326).
CAD (n = 45, 14%) No CAD (n = 281, 86%) P
Asymptomatic 0 (0%) 5 (2%) 1.0
Typical angina 14 (31%) 27 (10%) 0.20
Atypical angina 14 (31%) 90 (32%) 0.55
Dyspnea 21 (47%) 82 (29%) 0.06
Palpitations 37 (82%) 246 (88%) 1.0
Syncope 1 (2%) 19 (7%) 0.32
Figure 2. Receiver operating characteristic, sensitivity 
and specificity of high-sensitivity troponin for the 
diagnosis of relevant coronary artery disease in patients 
presenting with supraventricular tachycardia.
www.cardiologyjournal.org 645
Martin Murer et al., CAD in patients with supraventricular tachycardia
invasive coronary angiography in order to exclude 
or confirm CAD. 
The present study demonstrates a relatively 
low prevalence of CAD in this group of patients and 
thus questions the role of routine invasive coronary 
angiography. This study was not able to identify 
a Tn cut-off, which reliably predicts the presence 
of CAD in patients with SVT. The assessment of 
Tn in patients with SVT, who easily convert into 
sinus rhythm, can lead to unnecessary diagnostic 
tests or wrong diagnosis [14, 15]. SalimRezaie [15] 
postulated that the evaluation of Tn in patients with 
SVT should be reserved for patients with persist-
ing symptoms in the absence of an SVT-episode 
and for patients with abnormal ECG findings after 
conversion into sinus rhythm. On the other hand, 
increased Tn-levels in patients without CAD, 
independent of its etiology, tend to be a predic-
tor of worse outcomes [16]. Increased Tn-levels 
were found to accompany an increased mortality 
rate [17–20] and should be rated as an indicator 
of critical medical status [21]. The mortality risk 
of patients with a ten time increased Tn-level 
is twice as high as for patients with normal Tn-
-levels [22]. 
There are several reasons for Tn elevations 
in patients with SVT. Given the fact that Tn can 
be elevated even in patients < 21 years it is 
fair to conclude that the presence of CAD is not 
a condicio-sine-qua-non. From the pathophysi-
ologic point of view heart rate, duration of SVT 
and mean arterial blood pressure, end-diastolic 
left ventricular pressure all have an important 
impact on coronary perfusion and could lead 
to mild ischemia and troponin “leak” [23]. It is 
also important to realize that troponin elevation 
does not always indicate cell death and therefore 
Table 4. Comparison of supraventricular tachycardia between patients with and without coronary  
artery disease (CAD) (n = 326).
CAD (n = 45, 14%) No CAD (n = 281, 86%) P
AF 8 (7%) 100 (93%) 0.60
AFL 18 (35%) 33 (65%) 0.04
AF + AFL 3 (10%) 26 (90%) 0.21
AVNRT 14 (15%) 81 (85%) 1.0
AVRT 0 (0%) 15 (100%) 0.16
WPW 0 (0%) 15 (100%) 0.16
Ectopic AT 3 (30%) 7 (70%) 0.08
AF — atrial fibrillation; AFL — atrial flutter; AVNRT — atrioventricular nodal re-entry tachycardia; AVRT — atrioventricular re-entry tachycardia; 
AT — atrial tachycardia; WPW — Wolff-Parkinson-White syndrome
Table 5. Comparison of high-sensitivity troponin between patients with and without coronary  
artery disease (CAD) (n = 67).
Total (n = 67, 14%) CAD (n = 12, 18%) No CAD (n = 55, 82%) P
Troponin-hs ≥ 0.014 µg/L 36 (54%) 10 (83%) 26 (47%) 0.17
Troponin-hs < 0.014 µg/L 31 (46%) 2 (17%) 29 (53%) 0.32
Figure 3. Comparison of high-sensitivity troponin between 
patients with and without coronary artery disease (CAD).
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myocardial ischemia is only one of probably many 
reasons for Tn elevation [24]. 
Patients should be evaluated with an estab-
lished risk-score to estimate the probability of 
CAD, e.g. Framingham Coronary Heart Disease 
Risk Score [25] and the decision to perform inva-
sive coronary angiography should be based on the 
risk-score rather than the presence of elevated 
Tn in SVT patients [26].
Limitations of the study
This study has several limitations, which need 
to be mentioned. It is a retrospective analysis from 
a single centre in Switzerland with all the limita-
tions of retrospective analysis. The indication to 
perform a coronary angiography was arbitrary 
and made on the clinical judgement of different 
operators. A prospective, multi-centre study could 
address this important question in a more appro-
priate way.
Conclusions
Measurement of Tn in patients presenting 
with SVT was not of assistance in reliably confirm-
ing or excluding CAD. Routine invasive coronary 
angiography is not warranted in patients undergo-
ing RFA and the decision should be made on clinical 
grounds rather than the presence of Tn elevation. 
Conflict of interest: None declared
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